BAJAJ BROKING

Notification close image
No new Notification messages
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

524752

DECIPHER

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

DECIPHER LABS LIMITED Share Price Update

As of the latest trading session, DECIPHER LABS LIMITED share price is currently at ₹ 10.5, which is up by ₹ 0.01 from its previous closing. Today, the stock has fluctuated between ₹ 10.19 and ₹ 10.92. Over the past year, DECIPHER LABS LIMITED has achieved a return of -40.76 %. In the last month alone, the return has been -5.49 %. Read More...

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

DECIPHER LABS LIMITED fundamentals


  • Market cap (Cr)

    [-]

  • P/E Ratio (TTM)

    [-]

  • Beta

    [-]

  • Book Value / share

    [-]

  • Return on equity

    [-]%

  • EPS (TTM)

    [-]

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    [-]

info icon alternate text
  • Market cap (Cr)

    10.60

  • P/E Ratio (TTM)

    -40.35

  • Beta

    0.34

  • Book Value / share

    8.40

  • Return on equity

    0.16%

  • EPS (TTM)

    0.00

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    0.06

info icon alternate text

DECIPHER LABS LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 0.85
Operating Expense 0.79
Net Profit 0.06
Net Profit Margin (%) 7.05
Earnings Per Share (EPS) 0.06
EBITDA 0.06
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 0.23
Operating Expense 0.39
Net Profit -0.17
Net Profit Margin (%) -73.91
Earnings Per Share (EPS) -0.17
EBITDA -0.16
Effective Tax Rate (%) 0.00
Particulars DEC 2024 (Values in Cr)
Revenue 0.16
Operating Expense 0.25
Net Profit -0.09
Net Profit Margin (%) -56.25
Earnings Per Share (EPS) -0.09
EBITDA -0.09
Effective Tax Rate (%) 0.00
Particulars SEP 2024 (Values in Cr)
Revenue 0.08
Operating Expense 0.16
Net Profit -0.06
Net Profit Margin (%) -75.00
Earnings Per Share (EPS) -0.06
EBITDA -0.06
Effective Tax Rate (%) 0.00
Particulars JUN 2024 (Values in Cr)
Revenue 0.38
Operating Expense 0.51
Net Profit -0.13
Net Profit Margin (%) -34.21
Earnings Per Share (EPS) -0.13
EBITDA -0.13
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 0.85
Operating Expense 1.32
Net Profit -0.44
Net Profit Margin (%) -51.76
Earnings Per Share (EPS) -0.44
EBITDA -0.42
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 3.53
Operating Expense 3.53
Net Profit 0.02
Net Profit Margin (%) 0.56
Earnings Per Share (EPS) 0.02
EBITDA 0.04
Effective Tax Rate (%) 0.00
Particulars MAR 2023 (Values in Cr)
Revenue 0.81
Operating Expense 1.24
Net Profit -2.62
Net Profit Margin (%) -323.45
Earnings Per Share (EPS) -2.59
EBITDA -2.58
Effective Tax Rate (%) 0.75
Particulars MAR 2022 (Values in Cr)
Revenue 0.99
Operating Expense 0.68
Net Profit 0.36
Net Profit Margin (%) 36.36
Earnings Per Share (EPS) 0.36
EBITDA 0.41
Effective Tax Rate (%) 0.00
Particulars MAR 2021 (Values in Cr)
Revenue 0.98
Operating Expense 1.02
Net Profit 0.10
Net Profit Margin (%) 10.20
Earnings Per Share (EPS) 0.10
EBITDA 0.16
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Book Value / Share 21.64
ROE % -6.75
ROCE % -3.11
Total Debt to Total Equity 0.02
EBITDA Margin -0.71
Particulars MAR 2023 (Values in Cr)
Book Value / Share 22.98
ROE % 15.91
ROCE % 9.46
Total Debt to Total Equity 0.24
EBITDA Margin 7.03
Particulars MAR 2022 (Values in Cr)
Book Value / Share 23.93
ROE % 55.79
ROCE % 38.01
Total Debt to Total Equity 0.71
EBITDA Margin 20.97
Particulars MAR 2021 (Values in Cr)
Book Value / Share 13.55
ROE % 8.35
ROCE % 10.82
Total Debt to Total Equity 1.05
EBITDA Margin 7.43
Particulars MAR 2020 (Values in Cr)
Book Value / Share 12.44
ROE % 8.84
ROCE % 12.31
Total Debt to Total Equity 0.76
EBITDA Margin 11.63
Particulars MAR 2024 (Values in Cr)
Book Value / Share 8.84
ROE % 0.16
ROCE % 0.16
Total Debt to Total Equity 0.00
EBITDA Margin 1.13
Particulars MAR 2023 (Values in Cr)
Book Value / Share 8.82
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -33.33
Particulars MAR 2022 (Values in Cr)
Book Value / Share 11.41
ROE % 2.20
ROCE % 2.19
Total Debt to Total Equity 0.01
EBITDA Margin 41.41
Particulars MAR 2021 (Values in Cr)
Book Value / Share 11.05
ROE % 0.61
ROCE % 0.72
Total Debt to Total Equity 0.02
EBITDA Margin 16.33
Particulars MAR 2020 (Values in Cr)
Book Value / Share 10.96
ROE % 1.39
ROCE % 1.37
Total Debt to Total Equity 0.03
EBITDA Margin 11.97
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 9.31
Total Assets 33.63
Total Liabilities 33.63
Total Equity 21.86
Share Outstanding 10100000
Price to Book Ratio 1.67
Return on Assets (%) -4.98
Return on Capital (%) -7.66
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 7.41
Total Assets 28.16
Total Liabilities 28.16
Total Equity 23.20
Share Outstanding 10100000
Price to Book Ratio 1.61
Return on Assets (%) -9.52
Return on Capital (%) -11.1
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 15.40
Total Assets 41.94
Total Liabilities 41.94
Total Equity 24.16
Share Outstanding 10100000
Price to Book Ratio 4.64
Return on Assets (%) 27.13
Return on Capital (%) 33.01
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 6.97
Total Assets 38.72
Total Liabilities 38.72
Total Equity 13.68
Share Outstanding 10100000
Price to Book Ratio 3.03
Return on Assets (%) 3.62
Return on Capital (%) 6.25
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1.46
Total Assets 35.38
Total Liabilities 35.38
Total Equity 12.56
Share Outstanding 10100000
Price to Book Ratio 1.72
Return on Assets (%) 3.11
Return on Capital (%) 5
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.02
Total Assets 12.76
Total Liabilities 12.76
Total Equity 8.92
Share Outstanding 10100000
Price to Book Ratio 1.67
Return on Assets (%) 0.18
Return on Capital (%) 0.26
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.05
Total Assets 8.98
Total Liabilities 8.98
Total Equity 8.90
Share Outstanding 10100000
Price to Book Ratio 1.61
Return on Assets (%) -29.11
Return on Capital (%) -29.4
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.04
Total Assets 11.60
Total Liabilities 11.60
Total Equity 11.52
Share Outstanding 10100000
Price to Book Ratio 4.64
Return on Assets (%) 3.10
Return on Capital (%) 3.13
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.01
Total Assets 11.39
Total Liabilities 11.39
Total Equity 11.16
Share Outstanding 10100000
Price to Book Ratio 3.03
Return on Assets (%) 0.84
Return on Capital (%) 0.85
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.02
Total Assets 11.64
Total Liabilities 11.64
Total Equity 11.06
Share Outstanding 10100000
Price to Book Ratio 1.72
Return on Assets (%) 1.44
Return on Capital (%) 1.49
Particulars MAR 2024 (Values in Cr)
Net Income -1.21
Cash from Operations 4.85
Cash from Investing -1.79
Cash from Financing -1.16
Net change in Cash 1.89
Free Cash Flow 4.91
Particulars MAR 2023 (Values in Cr)
Net Income -4.15
Cash from Operations -1.56
Cash from Investing -4.27
Cash from Financing -2.15
Net change in Cash -7.99
Free Cash Flow -0.78
Particulars MAR 2022 (Values in Cr)
Net Income 12.35
Cash from Operations 8.26
Cash from Investing -0.45
Cash from Financing 1.30
Net change in Cash 9.11
Free Cash Flow 8.46
Particulars MAR 2021 (Values in Cr)
Net Income 2.14
Cash from Operations 1.83
Cash from Investing -0.31
Cash from Financing 3.98
Net change in Cash 5.50
Free Cash Flow 2.14
Particulars MAR 2020 (Values in Cr)
Net Income 1.46
Cash from Operations -15.17
Cash from Investing -0.12
Cash from Financing 16.36
Net change in Cash 1.05
Free Cash Flow -14.93
Particulars MAR 2024 (Values in Cr)
Net Income 0.02
Cash from Operations -0.02
Cash from Investing 0.00
Cash from Financing 0.00
Net change in Cash -0.02
Free Cash Flow -0.02
Particulars MAR 2023 (Values in Cr)
Net Income -2.63
Cash from Operations -0.07
Cash from Investing 0.08
Cash from Financing 0.00
Net change in Cash 0.00
Free Cash Flow -0.07
Particulars MAR 2022 (Values in Cr)
Net Income 0.35
Cash from Operations 0.54
Cash from Investing -0.38
Cash from Financing -0.13
Net change in Cash 0.02
Free Cash Flow 0.67
Particulars MAR 2021 (Values in Cr)
Net Income 0.10
Cash from Operations 0.27
Cash from Investing -0.18
Cash from Financing -0.09
Net change in Cash -0.01
Free Cash Flow 0.46
Particulars MAR 2020 (Values in Cr)
Net Income 0.16
Cash from Operations -0.01
Cash from Investing -0.06
Cash from Financing 0.09
Net change in Cash 0.01
Free Cash Flow 0.09
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 31.89 13.02 1.74 244.38 30.00 / 68.85
BLISS GVS PHARMA LTD 153.20 15.17 1.53 1617.36 105.05 / 190.65
CIPLA LTD 1560.90 23.38 4.04 126082.33 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 345.20 9.72 2.80 1015.96 219.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 31.89 17.33 5.03 244.38 30.00 / 68.85
AMRUTAJAN HEALTH LTD 750.80 39.81 6.64 2170.61 548.05 / 829.00
ASTRAZENECA PHARMA IND LT 9065.70 107.17 29.42 22664.25 6222.35 / 10653.05
BLISS GVS PHARMA LTD 153.20 22.90 1.52 1617.36 105.05 / 190.65

DECIPHER LABS LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
10.50 0.09 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 10.60
  • 26 Days 10.70
  • 10 Days 10.60
  • 50 Days 10.90
  • 12 Days 10.60
  • 100 Days 11.40
  • 20 Days 10.70
  • 200 Days 12.40
10.56 PIVOT

First Support

10.26

First Resistance

10.80

Second Support

10.02

Second Resistance

11.10

Third Support

9.72

Third Resistance

11.34

RSI

45.23

ADX

37.21

MACD

-0.13

Williams % R

-64.49

Commodity Channel Index (CCI)

-54.85

Date

2025-09-11

Week

8941.00

Same Day

4264.00

Month

5245.00

1 Year

0.35

3 Year

0.42

Over 1 Month

-5.49%

down

Over 1 Year

-40.76%

down

Over 3 Months

-8.46%

down

Over 3 Years

-39.66%

down

Over 6 Months

-9.56%

down

Over 5 Years

-13.00%

down

Transparent Pricing, 360° Services

Choose a plan that best suits your goals & needs.

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : 2500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Expert Stock Research tick Experienced Dealer Support

DECIPHER LABS LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
83.57%
Promoter Holdings
16.42%
FII
0.0%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Ajjarapu Janakiram 1659075.0 (16.43%) Shareholding of Promoter and Promoter Group
Seshu Srinivas Akula 384273.0 (3.8%) Public Shareholding
Sushant Mohan Lal 216315.0 (2.14%) Public Shareholding
Suriadoss Elumalai 143655.0 (1.42%) Public Shareholding
Cyril Sebastian 131250.0 (1.3%) Public Shareholding
Suman Chepuri 127732.0 (1.26%) Public Shareholding

News

Left Arrow
Right Arrow

DECIPHER LABS LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

DECIPHER LABS LIMITED Share Price

Decipher Labs Ltd. (formerly known as Combat Drugs Ltd) was incorporated as a Private Limited Company in September, 1986 and was
converted into a Public Limited Company in Jun.'92. The company was promoted by Suchit Mohan Lal and Ajay Karan.

The Company is a professionally managed, well established, diversified Public Limited Company, engaged in the Manufacture & Marketing of Pharmaceuticals and allied products and services and providing Services and key Solutions in Information Technology Industry. Since inception, the Company has been manufacturing & marketing its branded formulations and custom manufacturing for various companies besides supplies of various Bulk drugs, chemicals and Finished Formulations. During the years of operations, it has garnered a reputation as a quality provider in the Pharmaceutical industry and the Products marketed by the Company have been well accepted by the Trade and Medical Fraternity across India.?

The Company also diversified interest in the field on Information Technology and has developed a name for itself as a key solution provider in the field of associated technologies. It expanded by reviving the Information Technology wing and started dealing and reviving its associations into the Information Technology Industry. To increase presence in the Information Technology segment, the Company acquired Decipher Software Solutions LLC in USA to add good volumes to the overall turnover and Profits of the Company.

The Company came out with a public issue of 23.23 lac equity shares at par aggregating Rs 2.32 cr in Nov.'94. The proceeds of the issue were utilised to part-finance a Rs 3.25-cr project to expand the existing manufacturing facilities for pharmaceutical formulations and to diversify into the manufacture of sterile powder injectables.

CDL started commercial production in Jul.'87 on a loan-licence basis. The company acquired a full-fledged manufacturing unit located at Balanagar, Hyderabad, on lease from Fairchild Laboratories and commenced commercial production in Aug.'88. In Jul.'92 the manufacturing activities were shifted to the present leased premises at Kushaiguda, Hyderabad. In this unit various pharmaceutical formulations such as tablets, capsules and liquids are being manufactured. The product range of CDL comprises vital anti-bacterial drugs, antibiotic drugs, anti-inflammatory drugs, haematenic drugs and protein tonic. CDL has developed in-house technology for the manufacture of dispersible and sustained release formulations. The company is exploring the possibilities of exporting its products to Nigeria and West Indies.

During the year 1995-96, the expansion programme undertaken by the company was successfully completed and the unit at Yellampet has become operational.

During 1996-97, the company has expanded its operations to new areas. It has expanded its product range by introduction of Liquid Orals. The product 'HB 2' has been well accepted in the market. The company has also filled its application for obtaining the (c)GMP and WHO GMP Certificate.

Parent organization Indian Private
NSE symbol [-]
Founded 1986
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Decipher Labs Ltd?

Answer Field

Decipher Labs Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 10.50 as on Sep 12 2025 03:24 PM.

What is the Market Cap of Decipher Labs Ltd Share?

Answer Field

The market cap of Decipher Labs Ltd for NSE ₹ 0.00 & for BSE ₹ 10.60 as on Sep 12 2025 03:24 PM.

What is the 52 Week High and Low of Decipher Labs Ltd?

Answer Field

The 52 Week High and Low of Decipher Labs Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 18.90 and ₹ 9.61.

What is 1 year return for Decipher Labs Ltd?

Answer Field

The 1 year returns on the stock has been -40.76%.

What is the P/E Ratio of Decipher Labs Ltd Share?

Answer Field

As on Sep 12 2025 03:24 PM the price-to-earnings (PE) ratio for Decipher Labs Ltd share is -40.35.

What is the PB ratio of Decipher Labs Ltd Share?

Answer Field

As on Sep 12 2025 03:24 PM, the price-to-book (PB) ratio for Decipher Labs Ltd share is 8.40.

How to Buy Decipher Labs Ltd Share?

Answer Field

You can trade in Decipher Labs Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Decipher Labs Ltd Share on Bajaj Broking App?

Answer Field

To buy Decipher Labs Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Decipher Labs Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

close-image

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
close-image

Get Free Demat Account*

+91